Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Inflamm Bowel Dis ; 22(6): 1296-305, 2016 06.
Article in English | MEDLINE | ID: mdl-27104821

ABSTRACT

BACKGROUND: There is no standardized validated experimental model used to predict human drug response, and the choice of model is not based on systematic evidence. Therefore, we decided to systematically investigate which models are currently used by selecting studies from literature that use prescribed inflammatory bowel disease medication as a positive control. METHODS: A search of PubMed was performed using terms describing experimental colitis models and the drugs used in corresponding clinical practice followed by the application of an animal filter. Each article was read and scored using a predesigned form describing the characteristics of the study (17 items), a quality assessment (10 items) completed by a meta-analysis. RESULTS: One hundred ninety-four unique articles were included that met the selection criteria. A large heterogeneity was found regarding the characteristics of the animals used, induction methods, treatment protocol, and reporting quality. If categorized by colitis model only a small number of studies used a chronic model (10/194). Almost all use acute chemical models that investigate a response to epithelial damage, rather than chronic colitis. Fifty-six percent used a TNBS model and 20% used a dextran sodium sulfate model. In these models, an ameliorating effect of 5-ASA and corticosteroids was demonstrated and also a difference in outcome when male or female animals are used. CONCLUSIONS: This scope describes a huge heterogeneity in study designs for preclinical drug efficacy. In addition, more than three-quarters of the studies used an acute model irrelevant for testing new treatment options for inflammatory bowel disease.


Subject(s)
Biomedical Research/standards , Colitis/drug therapy , Disease Models, Animal , Drug Evaluation, Preclinical , Research Design/standards , Adrenal Cortex Hormones/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Colitis/pathology , Mesalamine/therapeutic use , Sex Factors
2.
Nutrients ; 7(10): 8518-31, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26501315

ABSTRACT

In this study, we evaluated the effects of dietary plant sterols and stanols as their fatty acid esters on the development of experimental colitis. The effects were studied both in high- and low-fat diet conditions in two models, one acute and another chronic model of experimental colitis that resembles gene expression in human inflammatory bowel disease (IBD). In the first experiments in the high fat diet (HFD), we did not observe a beneficial effect of the addition of plant sterols and stanols on the development of acute dextran sulphate sodium (DSS) colitis. In the chronic CD4CD45RB T cell transfer colitis model, we mainly observed an effect of the presence of high fat on the development of colitis. In this HFD condition, the presence of plant sterol or stanol did not result in any additional effect. In the second experiments with low fat, we could clearly observe a beneficial effect of the addition of plant sterols on colitis parameters in the T cell transfer model, but not in the DSS model. This positive effect was related to the gender of the mice and on Treg presence in the colon. This suggests that especially dietary plant sterol esters may improve intestinal inflammation in a T cell dependent manner.


Subject(s)
Colitis/diet therapy , Colon/drug effects , Diet, Fat-Restricted , Diet, High-Fat , Inflammatory Bowel Diseases/pathology , Phytosterols/therapeutic use , T-Lymphocytes/metabolism , Acute Disease , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antigens, CD , Brassica rapa/chemistry , Chronic Disease , Colitis/drug therapy , Colitis/etiology , Colitis/immunology , Colon/pathology , Dietary Fats/administration & dosage , Dietary Fats/pharmacology , Dietary Fats/therapeutic use , Esters , Fatty Acids/pharmacology , Fatty Acids/therapeutic use , Fatty Acids, Monounsaturated , Female , Inflammation/diet therapy , Inflammation/drug therapy , Inflammation/immunology , Inflammatory Bowel Diseases/diet therapy , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , Male , Mice, Inbred C57BL , Phytosterols/administration & dosage , Phytosterols/pharmacology , Phytotherapy , Plant Oils/chemistry , Rapeseed Oil , Sitosterols/administration & dosage , Sitosterols/pharmacology , Sitosterols/therapeutic use
3.
Clin Infect Dis ; 46(11): 1677-82, 2008 Jun 01.
Article in English | MEDLINE | ID: mdl-18433338

ABSTRACT

BACKGROUND: Antibiotic resistance among microbes urgently necessitates the development of novel antimicrobial agents. Since ancient times, honey has been used successfully for treatment of infected wounds, because of its antibacterial activity. However, large variations in the in vitro antibacterial activity of various honeys have been reported and hamper its acceptance in modern medicine. METHODS: We assessed the in vitro bactericidal activity of Revamil (Bfactory), a medical-grade honey produced under controlled conditions, and assessed its efficacy for reduction of forearm skin colonization in healthy volunteers in a within-subject-controlled trial. RESULTS: With Bacillus subtilis as a test strain, we demonstrated that the variation in bactericidal activity of 11 batches of medical-grade honey was <2-fold. Antibiotic-susceptible and -resistant isolates of Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa, Enterobacter cloacae, and Klebsiella oxytoca were killed within 24 h by 10%-40% (vol/vol) honey. After 2 days of application of honey, the extent of forearm skin colonization in healthy volunteers was reduced 100-fold (P < .001), and the numbers of positive skin cultures were reduced by 76% (P < .001). CONCLUSIONS: Revamil is a promising topical antimicrobial agent for prevention or treatment of infections, including those caused by multidrug-resistant bacteria.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteria/drug effects , Honey , Skin Diseases, Bacterial/drug therapy , Anti-Bacterial Agents/pharmacology , Bacteria/growth & development , Humans , Microbial Sensitivity Tests
4.
Acta Gastroenterol Belg ; 69(4): 406-12, 2006.
Article in English | MEDLINE | ID: mdl-17343084

ABSTRACT

Evidence is increasing that a defect in apoptosis is involved in the pathogenesis of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). CD seems to be the cause of an intrinsic defect in the apoptotic pathway of (autoreactive) T cells, resulting in excessive T cell responses. In UC, an increased rate of apoptosis of epithelial cells is observed. In this review we will describe apoptotic mechanisms and their association to IBD. In addition, we will review how specific therapeutic approaches interact at different levels with the apoptotic pathway.


Subject(s)
Apoptosis/physiology , Inflammatory Bowel Diseases/physiopathology , Cell Cycle/physiology , Humans , Intestinal Mucosa/cytology , Intestinal Mucosa/physiology , T-Lymphocytes/physiology
5.
J Nucl Med ; 45(10): 1759-65, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15471846

ABSTRACT

UNLABELLED: Blockade of lymphocyte recruitment to the intestinal mucosa is considered a useful therapy for inflammatory bowel disease (IBD) and anti-alpha4 antibodies have clinical benefit in patients with active Crohn's disease. The aim of this study was to evaluate a scintigraphic technique to assess lymphocyte homing to the colon in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis (TNBS colitis) in vivo. METHODS: TNBS-sensitized and nonsensitized murine total lymphocytes or CD4+ lymphocytes were radiolabeled with 111In-oxinate. Cells were injected into control mice (n = 5) or mice with TNBS colitis (n = 5). Specific abdominal radioactive uptake was determined by SPECT using a dedicated pinhole system 48 h after cell transfer. Radioactive colon uptake was correlated with histology and colon weight as parameters of inflammation. RESULTS: The radioactive colon uptake was most evident in mice with TNBS colitis that received sensitized lymphocytes (uptake ratio [mean +/- SEM], 0.51 +/- 0.03 vs. 0.22 +/- 0.04; P = 0.004). The sensitized 111In-labeled lymphocytes exacerbated colitis compared with nonsensitized lymphocytes. The colon uptake correlated well with both colon weight and histologic score (R2 = 0.836 and 0.933, respectively). The use of purified 111In labeled CD4+ lymphocytes resulted in a similar scintigraphic pattern. Administration of an anti-alpha4 antibody decreased radioactivity colon uptake of the (111)In-labeled cells compared with the control antibody in mice with TNBS colitis (uptake ratio, 0.72 +/- 0.14 to 0.33 +/- 0.03; P = 0.012). CONCLUSION: Animal pinhole SPECT can be applied for temporal and spatial analysis of the lymphocyte homing process in experimental colitis. This technique makes possible the in vivo evaluation of therapeutic efficacy of new drugs that interfere with lymphocyte migration. Moreover, colon uptake of radioactivity can be used as a parameter of disease activity in experimental colitis.


Subject(s)
CD4-Positive T-Lymphocytes/diagnostic imaging , CD4-Positive T-Lymphocytes/immunology , Colitis/diagnostic imaging , Colitis/immunology , Indium Radioisotopes/immunology , Receptors, Lymphocyte Homing/immunology , Animals , Colitis/blood , Colitis/chemically induced , Drug Evaluation, Preclinical , Female , Indium Radioisotopes/blood , Lymphocyte Activation/immunology , Mice , Mice, Inbred BALB C , Radionuclide Imaging , Receptors, Lymphocyte Homing/blood , Reproducibility of Results , Sensitivity and Specificity , Trinitrobenzenesulfonic Acid
6.
J Clin Invest ; 110(10): 1539-48, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12438451

ABSTRACT

Apart from its role in the synthesis of protein and nitric oxide (NO), and in ammonia detoxification, the amino acid arginine exerts an immunosupportive function. We have studied the role of arginine in immune defense mechanisms in the developing postnatal immune system. In suckling mice, arginine is produced in the small intestine. In F/A-2(+/+) transgenic mice, which overexpress arginase in their enterocytes, circulating and tissue arginine concentrations are reduced to 30-35% of controls. In these mice, the development and composition of the T cell compartment did not reveal abnormalities. However, in peripheral lymphoid organs and the small intestine, B cell cellularity and the number and size of Peyer's patches were drastically reduced, and serum IgM levels were significantly decreased. These phenotypes could be traced to an impaired transition from the pro- to pre-B cell stage in the bone marrow. Cytokine receptor levels in the bone marrow were normal. The development of the few peripheral B cells and their proliferative response after in vitro stimulation was normal. The disturbance in B cell maturation was dependent on decreased arginine levels, as this phenotype disappeared upon arginine supplementation and was not seen in NO synthase- or ornithine transcarbamoylase-deficient mice. We conclude that arginine deficiency impairs early B cell maturation.


Subject(s)
Arginine/deficiency , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Lymphoid Tissue/growth & development , Lymphoid Tissue/metabolism , Animals , Arginase/genetics , B-Lymphocytes/immunology , Cell Differentiation , Lymphocyte Activation , Lymphoid Tissue/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , Mice, Transgenic , Nitric Oxide Synthase/deficiency , Nitric Oxide Synthase/genetics , Peyer's Patches/growth & development , Peyer's Patches/immunology , Peyer's Patches/metabolism , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL